Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. - Wikidata - wikimedia - TriplyDB

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

http://www.wikidata.org/entity/Q34090872

about

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis Pathophysiology guided treatment of nonalcoholic steatohepatitis Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer Role of diet on non-alcoholic fatty liver disease: An updated narrative review Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.Promising therapies for treatment of nonalcoholic steatohepatitis.Cost-utility analysis of nonalcoholic steatohepatitis screening.Hepatic fat during fasting and refeeding by MRI fat quantification.Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis.Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease PharmGKB summary: very important pharmacogene information for CYP4F2 Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.Non-alcoholic fatty liver disease in 2015.Ethnicity and nonalcoholic fatty liver disease Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease.Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up st Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis Association between metabolic syndrome and liver histology among NAFLD patients without diabetes.Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.Pioglitazone: side effect and safety profile.Pathophysiology of NASH: perspectives for a targeted treatment.Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease Quantification of liver fat with magnetic resonance imaging.Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

P2860

Q24625697-B11370E0-BFE0-477E-BB31-DF61C9052ECC Q26827117-D9527D1E-57AE-4160-8B6B-D73B7D65160A Q26992106-EA8E232B-C4F2-4F95-9062-724B275D9B42 Q27000333-81EB4B6F-59F0-43BD-81CC-694BF6271DF0 Q30241387-A0375C35-DB19-4763-AB3D-EA63AAC64077 Q30248578-BA7913F0-C728-4E65-B1F3-2ED68A9BB955 Q30385602-8B7054E7-7C8E-404E-AE0B-17D51607A438 Q30769371-422463CB-4844-4203-B188-C34F4D706358 Q33568261-8CBBFA65-9A62-439C-9051-E9EEB7E31FBB Q33851563-AEDC6D7E-F503-4380-9CC2-42AAF66CA84C Q33937311-03DE0895-2CF8-41BF-88E7-EF2494E5FB60 Q34069352-4100CD1E-6F9D-443B-9933-070287743987 Q34101263-FEEAAF28-DC3E-4B8D-96AB-821C061D7643 Q34664072-9BA05BFC-0C18-447A-B7F6-9D1F7DDEBAEA Q34758973-136ED513-98E3-4E96-ABF1-AACF290EA007 Q34946422-4B896843-D674-4E96-B328-81DC7721B1FB Q35715883-83373FE8-B938-405C-BB26-0B5981B610BF Q35754063-BEE73A93-CE85-4C01-9122-9299887E0947 Q35769495-02040082-2728-4388-BB5E-05F91628CE5A Q35826420-164E7DE8-CD2B-427F-880B-B39AAD68B4CA Q35860576-7687AD06-4153-4FCD-90ED-20E0221FA4CA Q35993416-410D1218-7288-482C-A2E9-B2C1F5B2D962 Q36123904-4CD4750B-F5E9-4D45-A07B-F3EC1D4F449C Q36192489-AF267D47-5699-4C7E-957E-4E4AA79A3E2E Q36205001-1973D99A-C08B-45FF-9ADB-6F5E540DF43E Q36438251-E272136B-B2E0-4924-8CD1-8BE3309ECF92 Q36785616-0A5EC6AB-1144-42EB-AE99-AC58B41C8C93 Q36795373-0F4FF0A2-837F-49E9-B84C-10158A911796 Q37029735-C65CE1B0-589D-4168-AD1C-41C5ACCFEEA6 Q37141885-46B31C08-290C-4549-92DA-0E633D4837F4 Q37177461-947F2B61-E3ED-4EC4-B72B-91F2D88BD0A0 Q37454017-5AD9E56B-A5C8-414B-A325-91F7C00A63C2 Q37563114-2D65A2F7-AE1D-4269-82DF-B9837D841EBB Q37693238-F9D5B9EF-A95D-45C5-82D0-EF82A6484CF2 Q37696508-04AAB787-37D0-4CF6-A9A1-7EEB4181A4D1 Q37699476-8138B050-2D44-458C-B4B8-5D5F9D3C531E Q37704752-DF527CEF-0C29-4A4F-8152-F53A65CBAF8F Q37811338-0B2636C3-2E78-40D5-B2E6-57ECECC00C30 Q37847181-0243FF1F-2DBC-4162-B1B9-824E05621A8A Q38018841-29BF6738-E653-446F-A294-E0D9E9D88EE1

P2860

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

http://www.wikidata.org/entity/Q34090872

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@ast

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@en

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@nl

type

label

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@ast

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@en

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@nl

prefLabel

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@ast

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@en

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@nl

P1433

Q34090872-692DE577-6C6A-4872-B0AF-F0F86E913262

P1476

Q34090872-AFD719A8-B7F5-4C8C-9A0F-C0E25F54526F

P2093

Q34090872-21D42A38-043B-4AB5-9F0C-EB8F551AA51D

Q34090872-2EB00766-12BA-49E4-AA89-730693595FF6

Q34090872-31005D96-E158-4EA8-A01F-996DD8231164

Q34090872-3CA4DC1D-8728-463D-B0D4-444390FC8C9E

Q34090872-7FB1875E-1F13-45D9-84F3-8A668F67107A

Q34090872-9F55C4CB-52ED-4A30-B440-90AF926CCEFE

Q34090872-B964255D-C8B4-4182-98F5-AE946EA5470E

Q34090872-E3BCC991-82F0-4F40-85D9-F47B263A380D

P2860

Q34090872-0645BE4C-7A2E-454B-893E-F27B8802A26D

Q34090872-084CCFC3-7C45-42DE-844B-644ACA593776

Q34090872-0A6AA654-EBF6-451A-978F-4DE554AAC239

Q34090872-11A95DAA-1E5C-479D-A5B6-1880607D599A

Q34090872-248EC773-3092-414C-A7F4-393AE89DEEA5

Q34090872-2F1A4ECF-7309-4AAD-A790-4301E0A182F5

Q34090872-302982A1-F290-47FC-AACA-C1783488134D

Q34090872-3A477E0C-E4C4-4E0D-BC27-2424A2969348

Q34090872-3ABDD3B7-8F57-4D32-9714-C138D2E934EC

Q34090872-3D4BF09D-BE15-4D51-84B1-B97269AB9191

P304

Q34090872-DC6AC011-49B6-453D-99F4-5E43A4E11A09

P31

Q34090872-EFD2DBDE-A7EA-4E7E-BE48-7CE6EEF18207

P356

Q34090872-E8AB6678-5E78-4296-B62E-220FC5D68A07

P407

Q34090872-2438E509-070E-4DF0-98C9-7092C093400E

P433

Q34090872-8E7E3C8F-FD34-4F97-8B69-8B0C5506F3C9

P478

Q34090872-347FEBE2-85FE-45E1-862A-D29CC8B473DA

P50

Q34090872-C734152B-84DE-4991-AC7B-7007F8B5CCE0

P577

Q34090872-1DBA18A1-C3F2-4290-A239-92B6650C9120

P5875

Q34090872-C86FFCFB-0271-42C7-A057-B93FD08290A2

P698

Q34090872-BCCAE685-9A77-4C66-8800-B72074CC5364

P921

Q34090872-249B3579-6A78-48D8-BD75-800A6F4D1594

Q34090872-25F6D9F1-5B77-4926-B604-FD58121E65DF

Q34090872-91f944ed-483a-4390-8c9c-d2303303019b

Q34090872-B17943E5-23A5-4B27-AE1C-E311BC077A2F

P932

Q34090872-39DCCB20-1BA1-493F-A232-BDE75B030326

P356

J.CCT.2008.09.003

P1433

Contemporary Clinical Trials

P1476

Pioglitazone versus vitamin E ...... epatitis: PIVENS trial design.

@en

P2093

Arun J Sanyal

http://www.w3.org/2001/XMLSchema#string

Aynur Unalp

http://www.w3.org/2001/XMLSchema#string

James Tonascia

http://www.w3.org/2001/XMLSchema#string

Jay Hoofnagle

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

NASH CRN Research Group

http://www.w3.org/2001/XMLSchema#string

Naga P Chalasani

http://www.w3.org/2001/XMLSchema#string

Patricia R Robuck

http://www.w3.org/2001/XMLSchema#string

P2860

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States

Steatohepatitis: a tale of two "hits"?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Cytokines in alcoholic and nonalcoholic steatohepatitis.

P304

88-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCT.2008.09.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

David E. Kleiner

P577

2008-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23270567

http://www.w3.org/2001/XMLSchema#string

P698

18804555

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

2929909

http://www.w3.org/2001/XMLSchema#string